相关实验视频
Updated: Jun 1, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
药剂师主导的糖尿病患者数字健康干预:系统性审查
Alicia Christy1, Frisca Fernanda1, Widya Norma Insani1,2
1Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Sumedang Regency, Jatinangor, Indonesia.
Journal of multidisciplinary healthcare
|January 17, 2025
概括
药剂师主导的数字健康干预措施在糖尿病管理方面显示出混合的结果. 虽然一些研究表明降低HbA1c和改善坚持,但有效性取决于患者的参与和个性化的支持.
科学领域:
- 数字健康数字健康
- 药物治疗 药物治疗
- 糖尿病管理 糖尿病管理
背景情况:
- 数字健康干预为患者护理提供了新的方法.
- 药剂师参与数字健康正在增长为慢性疾病管理.
研究的目的:
- 系统地审查药剂师为糖尿病患者领导的数字健康干预措施.
- 评估这些干预措施对临床结果和药物坚持的影响.
主要方法:
- 来自PubMed的随机对照试验 (RCT) 的系统审查 (2005年1月 - 2024年5月).
- 包括专注于1型和2型糖尿病的研究,将数字干预 (电话,网络,移动) 与常规护理进行比较.
- 评估结果包括HbA1c降低,药物坚持和不良影响,遵循PRISMA指南.
主要成果:
- 包括19个RCT,其中电话监控是最常见的干预措施.
- 大约53%的研究显示HbA1c水平降低,而26%的研究发现没有显著差异.
- 在26%的研究中,药物坚持改善了,在11%的研究中没有观察到任何变化.
结论:
- 药剂师主导的糖尿病数字健康干预措施的有效性各不相同.
- 成功的关键因素包括患者参与,干预频率和个性化沟通.
- 需要进一步研究成本效益,以指导医疗保健政策.
相关概念视频
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes: Symptoms, Diagnosis, and Complications
500
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
500
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165

